The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Factors Influencing Mortality in Acromegaly
Abstract
Studies of acromegaly have shown a doubling of mortality compared with the general population. With the development of new modalities of treatment, it has become important to identify prognostic factors relating to mortality. Between 1964 and 2000, 208 acromegalic patients were followed for a mean of 13 yr at Auckland Hospital. Treatment was by surgery or radionuclide pituitary implantation, and all except 27 patients received pituitary radiation. Over the duration of the study, 72 patients died at a mean age of 61 +/- 12.8 yr. Those dying were significantly older at diagnosis, had a higher prevalence of hypertension and diabetes, and were more likely to have hypopituitarism. The observed to expected mortality ratio (O/E ratio) fell from 2.6 (95% confidence interval, 1.9-3.6) in those with last follow-up GH greater than 5 microg/liter to 2.5 (1.6-3.8), 1.6 (0.9-3), and 1.1 (0.5-2.1) for those with GH less than 5, less than 2, and less than 1 microg/liter, respectively (P < 0.001). Serum IGF-I, expressed as an SD score, was significantly associated with mortality, with O/E mortality ratios of 3.5 (95% confidence interval, 2.8-4.2) for those with an SD score greater than 2, 1.6 (0.6-2.6) for those with an SD score less than 2 (normal or low levels), and 1.0 (0.1-3) for those with an SD score less than zero. When assessed by multivariate analysis, last serum GH (P < 0.001), age, duration of symptoms before diagnosis (P < 0.03), and hypertension (P < 0.04) were independent predictors of survival. If IGF-I was substituted for GH, then survival was independently related to last IGF-I SD score (P < 0.02), indicating that GH and IGF-I act equivalently as predictors of mortality. These findings indicate that reduction of GH to less than 1 microg/liter or normalization of serum IGF-I reduces mortality to expected levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Premature mortality due to cardiovascular disease in hypopituitarism
Rosén, T., & Bengtsson, B.-Å. (1990) · The Lancet · doi:10.1016/0140-6736(90)91812-o · Cited by 1,402
Association between premature mortality and hypopituitarism
Tomlinson, J., Holden, N., Hills, R., Wheatley, K., Clayton, R., Bates, A., Sheppard, M., & Stewart, P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04006-x · Cited by 1,006
Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant
Trainer, P. J., Drake, W. M., Katznelson, L., Freda, P. U., Herman-Bonert, V., van der Lely, A. J., Dimaraki, E. V., Stewart, P. M., Friend, K. E., Vance, M. L., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200004203421604 · Cited by 879
Mortality and Cancer Incidence in Acromegaly: A Retrospective Cohort Study1
Orme, S. M., McNally, R. J. Q., Cartwright, R. A., & Belchetz, P. E. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.8.5007 · Cited by 805
Long-Term Mortality after Transsphenoidal Surgery and Adjunctive Therapy for Acromegaly1
Swearingen, B., Barker, F. G., Katznelson, L., Biller, B. M. K., Grinspoon, S., Klibanski, A., Moayeri, N., Black, P. M., & Zervas, N. T. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.10.5222 · Cited by 586
Determinants of clinical outcome and survival in acromegaly
Rajasoorya, C., Holdaway, I. M., Wrightson, P., Scott, D. J., & Ibbertson, H. K. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb03789.x · Cited by 565
Self-citationIncreased cerebrovascular mortality in patients with hypopituitarism
Bülow, B., Hagmar, L., Mikoczy, Z., Nordström, C., & Erfurth, E. M. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.d01-1749.x · Cited by 542
Wright, A. D., Hill, D. M., Lowy, C., & Fraser, T. R. (1970) · PubMed · Cited by 529
BENGTSSON, B., EDÉN, S., ERNEST, I., ODÉN, A., & SJÖGREN, B. (1988) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1988.tb15881.x · Cited by 528
EPIDEMIOLOGY OF ACROMEGALY IN THE NEWCASTLE REGION
ALEXANDER, L., APPLETON, D., HALL, R., ROSS, W. M., & WILKINSON, R. (1980) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1980.tb03135.x · Cited by 466
An audit of outcome of treatment in acromegaly
(1993) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a068816 · Cited by 466
Long-Term Mortality after Transsphenoidal Surgery and Adjunctive Therapy for Acromegaly
Swearingen, B. (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.10.3419 · Cited by 400
Holdaway, I. M., & Rajasoorya, C. (1999) · Pituitary · doi:10.1023/a:1009965803750 · Cited by 394
Self-citationAbosch, A., Tyrrell, J. B., Lamborn, K. R., Hannegan, L. T., Applebury, C. B., & Wilson, C. B. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.10.3411 · Cited by 361
Long‐term outcome and mortality after transsphenoidal adenomectomy for acromegaly
Beauregard, C., Truong, U., Hardy, J., & Serri, O. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01679.x · Cited by 300
Long-term treatment of acromegaly with bromocriptine.
Wass, J. A., Thorner, M. O., Morris, D. V., Rees, L. H., Mason, A. S., Jones, A. E., & Besser, G. M. (1977) · BMJ · doi:10.1136/bmj.1.6065.875 · Cited by 242
BARKAN, A. L., BEITINS, I. Z., & KELCH, R. P. (1988) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-67-1-69 · Cited by 239
The incidence of cerebrovascular accidents in patients with pituitary adenoma
Brada, M., Burchell, L., Ashley, S., & Traish, D. (1999) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00159-5 · Cited by 210
Current Treatment Guidelines for Acromegaly1
Melmed, S., Jackson, I., Kleinberg, D., & Klibanski, A. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.8.4995 · Cited by 210
Acromegaly: An epidemiological study
Etxabe, J., Gaztambide, S., Latorre, P., & Vazquez, J. A. (1993) · Journal of Endocrinological Investigation · doi:10.1007/bf03344942 · Cited by 177
Current Treatment Guidelines for Acromegaly
Melmed, S. K. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.8.2646 · Cited by 120
Ho, K. K. Y., & Welssberger, A. J. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb03787.x · Cited by 109
Risk Factors for Cerebrovascular Deaths in Patients Operated and Irradiated for Pituitary Tumors
Erfurth, E. M., Bülow, B., Svahn‐Tapper, G., Norrving, B. G., Odh, K., Mikoczy, Z., Björk, J., & Hagmar, L. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020526 · Cited by 103
Brabant, G. E. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.148s015 · Cited by 39
Sequelae to Acromegaly: Reversibility with Treatment of the Primary Disease
Lieberman, S., & Hoffman, A. R. (1990) · Hormone and Metabolic Research · doi:10.1055/s-2007-1004910 · Cited by 32
Acromegaly: factors affecting the long term outcome after surgical treatment
Wrightson, P., Rajasoorya, C., Holdaway, I. M., & Scott, D. J. A. (1994) · Journal of Clinical Neuroscience · doi:10.1016/0967-5868(94)90023-x · Cited by 10
Self-citationShimatsu, Yokogoshi, Saito, & Shimizu, S. (1998) · Journal of Endocrinological Investigation · Cited by 9
Cited by
Acromegaly: An Endocrine Society Clinical Practice Guideline
Katznelson, L., Laws, E. R., Melmed, S., Molitch, M. E., Murad, M. H., Utz, A., & Wass, J. A. H. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2700 · Cited by 1,786
Melmed, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra062453 · Cited by 1,160
A Consensus on Criteria for Cure of Acromegaly
Giustina, A., Chanson, P., Bronstein, M. D., Klibanski, A., Lamberts, S., Casanueva, F. F., Trainer, P., Ghigo, E., Ho, K., & Melmed, S. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2670 · Cited by 783
Guidelines for Acromegaly Management: An Update
Melmed, S., Colao, A., Barkan, A., Molitch, M., Grossman, A. B., Kleinberg, D., Clemmons, D., Chanson, P., Laws, E., Schlechte, J., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2421 · Cited by 764
Mortality in Acromegaly: A Metaanalysis
Dekkers, O. M., Biermasz, N. R., Pereira, A. M., Romijn, J. A., & Vandenbroucke, J. P. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1191 · Cited by 517
Metadata
- Authors
- Holdaway, I. M., Rajasoorya, R. C., & Gamble, G. D.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2004-02
- Volume
- 89
- Issue
- 2
- Pages
- 667-674
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2014729851
- Cited by
- 651
- References
- 27
- FWCI
- 24.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.